#BEGIN_DRUGCARD DB01719

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C30H52O23S3

# Chemical_IUPAC_Name:
(2R,3S,4R,5R,6S)-2-{[(2S,3S,4R,5R,6R)-6-{[(2S,3S,4R,5R,6S)-6-{[(2S,3S,4R,5R,6R)-6-{[(2S,3S,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-sulfanyloxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]sulfanyl}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]sulfanyl}-6-(hydroxymethyl)oxane-3,4,5-triol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Thio-Maltopentaose

# HET_ID:
TM5

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C30H52O23S3/c31-1-6-11(36)12(37)20(45)29(50-6)55-24-9(4-34)48-27(18(43)15(24)40)53-23-8(3-33)51-30(21(46)14(23)39)56-25-10(5-35)47-26(17(42)16(25)41)52-22-7(2-32)49-28(54)19(44)13(22)38/h6-46,54H,1-5H2/t6-,7-,8-,9-,10-,11-,12+,13+,14+,15+,16+,17+,18+,19+,20-,21+,22+,23+,24+,25+,26-,27-,28-,29+,30-/m0/s1

# InChI_Key:
InChIKey=HQMKYAZGNUQLJB-MPVXZSPKSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1719

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
876.915

# Molecular_Weight_Mono:
876.20615004

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
9CGT

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.5

# Predicted_LogS:
-0.96

# Predicted_Water_Solubility:
9.59e+01 g/l

# Primary_Accession_No:
DB01719

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936199

# PubChem_Substance_ID:
46504605

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03067

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H]1O[C@H](S[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]3CO)S[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](S)O[C@H]4CO)O[C@H]3CO)O[C@H]2CO)[C@@H](O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:25 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X68326

# Drug_Target_1_GenBank_ID_Protein:
39420

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>2157 bp
ATGTTTCAAATGGCCAAACGCGCATTCCTCAGCACCACACTGACCCTCGGCTTGCTTGCC
GGCAGCGCCCTGCCGTTCTTGCCAGCTTCCGCTGTATACGCCGATCCGGACACTGCTGTG
ACCAACAAACAGAGCTTCAGTACAGATGTGATCTACCAAGTATTTACGGATCGCTTTTTG
GACGGCAATCCCTCCAACAACCCCACCGGAGCCGCTTATGATGCCACATGCAGCAATTTG
AAGCTGTACTGCGGCGGAGACTGGCAAGGGTTAATCAACAAAATCAACGATAACTATTTC
AGTGATCTGGGTGTCACAGCGTTGTGGATCTCCCAGCCTGTCGAAAATATTTTTGCGACG
ATCAACTATAGCGGTGTAACCAATACTGCCTACCACGGCTACTGGGCTCGAGACTTCAAA
AAGACCAATCCGTACTTCGGCACGATGGCGGACTTTCAGAACCTGATTACGACGGCTCAT
GCCAAAGGCATCAAGATTGTCATTGACTTTGCACCGAATCACACCTCTCCAGCGATGGAA
ACCGACACCTCTTTTGCCGAAAATGGCAGACTGTACGATAACGGTACACTGGTAGGCGGT
TATACCAATGATACCAACGGGTACTTCCATCACAATGGCGGCTCCGACTTCTCTTCCCTG
GAGAACGGCATCTACAAAAACCTGTATGACCTGGCCGACTTCAACCACAATAATGCGACC
ATCGACAAATACTTCAAAGATGCGATCAAACTGTGGCTTGATATGGGCGTTGACGGTATT
CGGGTGGATGCGGTGAAACATATGCCTCTCGGTTGGCAAAAGAGCTGGATGTCCTCCATC
TACGCACACAAACCCGTGTTCACTTTTGGAGAATGGTTCTTGGGATCAGCTGCATCCGAT
GCAGATAACACGGATTTTGCTAACAAGTCTGGTATGAGCCTGCTCGACTTCCGCTTTAAC
TCTGCGGTGCGTAATGTGTTCCGTGACAACACGTCCAACATGTACGCTCTGGATTCCATG
ATTAACAGCACAGCTACGGACTACAACCAAGTGAACGATCAGGTGACGTTCATCGACAAC
CATGATATGGATCGTTTCAAAACAAGTGCGGTCAACAATCGCCGTCTGGAACAGGCTTTG
GCCTTCACATTGACTTCACGTGGTGTACCTGCCATCTACTATGGTACTGAACAGTATTTG
ACGGGGAATGGCGATCCAGATAACCGGGCCAAAATGCCTTCGTTCTCCAAATCCACTACA
GCTTTTAACGTCATAAGTAAACTCGCGCCTCTGCGCAAATCCAATCCGGCCATTGCCTAC
GGTTCCACACAGCAGCGCTGGATTAATAATGATGTATATGTTTATGAGCGTAAATTCGGC
AAGAGCGTAGCCGTTGTCGCGGTAAACCGCAATCTTTCCACGTCTGCAAGCATTACAGGG
TTAAGCACTTCCCTGCCTACAGGCTCATACACGGATGTGCTTGGCGGGGTGCTGAACGGA
AATAACATCACCTCCACGAATGGTAGCATTAACAACTTCACCCTTGCTGCGGGTGCAACG
GCAGTATGGCAATACACAACTGCCGAAACAACACCAACCATCGGTCATGTTGGTCCGGTT
ATGGGGAAACCCGGTAATGTGGTGACAATTGATGGCCGTGGATTCGGCTCGACGAAAGGC
ACGGTCTACTTCGGCACTACAGCGGTTACCGGAGCAGCGATTACGTCTTGGGAAGATACA
CAGATTAAAGTAACCATCCCTTCCGTTGCCGCTGGCAACTATGCAGTCAAAGTTGCGGCA
AGCGGGGTAAACAGCAATGCATACAACAACTTCACCATCCTGACTGGCGATCAGGTCACC
GTTCGCTTCGTCGTAAACAATGCGTCCACAACGCTTGGACAGAACCTCTATTTGACAGGC
AACGTAGCCGAGCTTGGCAACTGGAGCACCGGTTCGACTGCCATTGGACCCGCATTCAAT
CAGGTCATTCATCAATACCCAACCTGGTACTATGATGTCAGCGTACCGGCAGGCAAACAG
CTGGAGTTCAAATTTTTCAAGAAAAACGGTTCAACGATTACATGGGAAAGCGGTTCTAAC
CACACATTCACTACACCAGCGAGCGGAACAGCCACCGTTACGGTGAACTGGCAGTAA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
1368573	Nitschke L, Heeger K, Bender H, Schulz GE: Molecular cloning, nucleotide sequence and expression in Escherichia coli of the beta-cyclodextrin glycosyltransferase gene from Bacillus circulans strain no. 8. Appl Microbiol Biotechnol. 1990 Aug;33(5):542-6.
1826034	Klein C, Schulz GE: Structure of cyclodextrin glycosyltransferase refined at 2.0 A resolution. J Mol Biol. 1991 Feb 20;217(4):737-50.
2531228	Hofmann BE, Bender H, Schulz GE: Three-dimensional structure of cyclodextrin glycosyltransferase from Bacillus circulans at 3.4 A resolution. J Mol Biol. 1989 Oct 20;209(4):793-800.
9558324	Schmidt AK, Cottaz S, Driguez H, Schulz GE: Structure of cyclodextrin glycosyltransferase complexed with a derivative of its main product beta-cyclodextrin. Biochemistry. 1998 Apr 28;37(17):5909-15.
9738912	Parsiegla G, Schmidt AK, Schulz GE: Substrate binding to a cyclodextrin glycosyltransferase and mutations increasing the gamma-cyclodextrin production. Eur J Biochem. 1998 Aug 1;255(3):710-7.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2293

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
78047

# Drug_Target_1_Name:
Cyclomaltodextrin glucanotransferase

# Drug_Target_1_Number_of_Residues:
718

# Drug_Target_1_PDB_ID:
1CGT

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF00686	CBM_20
PF01833	TIG
PF02806	Alpha-amylase_C

# Drug_Target_1_Protein_Sequence:
>Cyclomaltodextrin glucanotransferase precursor
MFQMAKRAFLSTTLTLGLLAGSALPFLPASAVYADPDTAVTNKQSFSTDVIYQVFTDRFL
DGNPSNNPTGAAYDATCSNLKLYCGGDWQGLINKINDNYFSDLGVTALWISQPVENIFAT
INYSGVTNTAYHGYWARDFKKTNPYFGTMADFQNLITTAHAKGIKIVIDFAPNHTSPAME
TDTSFAENGRLYDNGTLVGGYTNDTNGYFHHNGGSDFSSLENGIYKNLYDLADFNHNNAT
IDKYFKDAIKLWLDMGVDGIRVDAVKHMPLGWQKSWMSSIYAHKPVFTFGEWFLGSAASD
ADNTDFANKSGMSLLDFRFNSAVRNVFRDNTSNMYALDSMINSTATDYNQVNDQVTFIDN
HDMDRFKTSAVNNRRLEQALAFTLTSRGVPAIYYGTEQYLTGNGDPDNRAKMPSFSKSTT
AFNVISKLAPLRKSNPAIAYGSTQQRWINNDVYVYERKFGKSVAVVAVNRNLSTSASITG
LSTSLPTGSYTDVLGGVLNGNNITSTNGSINNFTLAAGATAVWQYTTAETTPTIGHVGPV
MGKPGNVVTIDGRGFGSTKGTVYFGTTAVTGAAITSWEDTQIKVTIPSVAAGNYAVKVAA
SGVNSNAYNNFTILTGDQVTVRFVVNNASTTLGQNLYLTGNVAELGNWSTGSTAIGPAFN
QVIHQYPTWYYDVSVPAGKQLEFKFFKKNGSTITWESGSNHTFTTPASGTATVTVNWQ

# Drug_Target_1_Reaction:
Cyclizes part of a 1,4-alpha-D-glucan chain by formation of a 1,4-alpha-D-glucosidic bond

# Drug_Target_1_Signals:
1-34

# Drug_Target_1_Specific_Function:
Cyclizes part of a 1,4-alpha-D-glucan chain by formation of a 1,4-alpha-D-glucosidic bond

# Drug_Target_1_SwissProt_ID:
P30920

# Drug_Target_1_SwissProt_Name:
CDGT1_BACCI

# Drug_Target_1_Synonyms:
CGTase
Cyclodextrin-glycosyltransferase
Cyclomaltodextrin glucanotransferase precursor
EC 2.4.1.19

# Drug_Target_1_Theoretical_pI:
6.65

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01719
